Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¹ÝÀûÀÎ ½Å°æº´¼º ÅëÁõÀÇ Á¶Àý ¹× Ä¡·á

The General Management and Treatment of Neuropathic Pain

´ëÇÑÄ¡°úÀÇ»çÇùȸÁö 2011³â 49±Ç 6È£ p.327 ~ 333
Àü¾çÇö,
¼Ò¼Ó »ó¼¼Á¤º¸
Àü¾çÇö ( Chun Yang-Hyun ) - °æÈñ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç

Abstract


Clinically, treatment goal of neuropathic pain focused on not elimination of etiology but management and control of symptoms because we don¡¯t know certain about clear etiology of neuropathic pain yet. The drugs used for the management of neuropathic pain were classified as drugs with strong evidence for benefit(antidepressants, anticonvulsants, opioid analgesics etc.), modest evidence for benefit(mexiletine, carbamazepine, clonidine etc.), preliminary evidence for benefit(NSAIDs, dextromethorphan, topiramate etc.). Finally, the treatment for trigeminal neuralgia was outlined separately since this disorder responds to a different group of drugs than other neuropathic pain conditions.

Å°¿öµå

neuropathic pain; trigeminal neuralgia; antidepressants; anticonvulsants; carbamazepine

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI